

Barrett's oesophagus Committee meeting 11

Date: 01/11/2022
Location: Virtual meeting
Minutes: Final

NICE National Institute for
Health and Care Excellence

Committee members present:	
John Primrose (Chair)	(Present for notes 1-4)
Massimiliano Di Pietro (Topic adviser)	(Present for notes 1-4)
Stephen Brinkworth	(Present for notes 1-4)
Tom Crosby	(Present for notes 1-4)
James Gossage	(Present for notes 1-4)
Helen Griffiths	(Present for notes 1-4)
Gaius Longcroft-Wheaton	(Present for notes 1-4)
Sophie Nelson	(Present for notes 1-4)
Christopher Penniston	(Present for notes 1-4)
Alexander Phillips	(Present for notes 1-4)
Nigel Trudgill	(Present for notes 1-4)

In attendance:		
Victoria Axe	Guideline Commissioning Manager	(Present for notes 1-4)
Amy Crisp	Senior Project Manager	(Present for notes 1-4)
Stephen Deed	Information Specialist	(Present for notes 1-4)
Muksitur Rahman	Health Economist	(Present for notes 1-4)
Gill Ritchie	Guideline Lead	(Present for notes 1-4)
Melina Vasileiou	Senior Systematic Reviewer	(Present for notes 1-4)
Joanna Perkin	Editor	(Present for notes 1-4)

Apologies:	
Sophie Nelson	Committee member
Philip Kaye	Committee member
Kieran Foley	Committee member

1. Welcome and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to the eleventh meeting on Barrett’s oesophagus.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p>
2. Confirmation of matter under discussion, and declarations of interest
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were the stakeholder consultation responses to the draft guideline.</p> <p>The Chair asked everyone to verbally declare any new interests.</p> <p>The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>
3. Stakeholder consultation comments
<p>The technical team and committee discussed the stakeholder consultation comments and made necessary edits to the evidence reviews based on these.</p>
4. Any other business
<p>The Chair thanked the committee for their participation in this guideline.</p>